SFLO Overview

New ETF Launches: Pacer ETFs has introduced two new funds, the Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW) and the Pacer S&P SmallCap 600 Quality FCF Aristocrats Strategy (SCOW), focusing on companies with at least seven consecutive years of positive free cash flow.

Investment Focus and Fees: Both funds aim for capital appreciation with a focus on high free cash flow quality scores; MCOW charges 49 bps and SCOW charges 59 bps in fees, with top holdings in sectors like Information Technology and Consumer Discretionary.

Analyst Rating and Forecast: J.P. Morgan analyst Zach Parham maintains a Neutral rating on Civitas Resources, Inc. (CIVI) with a price target of $49, emphasizing the company's focus on debt reduction and free cash flow generation, aiming for $800 million in debt reduction by FY25.

Production Estimates and Market Performance: Parham estimates first-quarter oil production at 143.2 MBo/d and EBITDA at $799 million, aligning closely with consensus estimates, while CIVI shares recently traded down 0.52% to $36.24.

ETF Performance Highlights: On Friday, Lyft and Cleveland-cliffs saw increases of about 1% and 1.8%, respectively, with significant trading volumes, while Quanex Building Products surged by 10.9%.

Underperforming Component: Scholastic experienced a notable decline, trading down approximately 15.6%, making it the worst performer in the VictoryShares Small Cap Free Cash Flow ETF.

Vista Outdoor Inc. Transactions: Vista Outdoor is set to sell Revelyst to Strategic Value Partners for $1.125 billion and has amended its merger agreement with Czechoslovak Group to acquire The Kinetic Group for $2.225 billion, valuing the company at $3.35 billion.

Stockholder Benefits and Approvals: Upon completion of these transactions, Vista Outdoor stockholders are expected to receive approximately $45 per share in cash, with all necessary regulatory approvals already obtained and a closing date anticipated by January 2025.

Mpox Outbreak and Global Response: Authorities in Europe and China are increasing screening for a new strain of mpox, known as clade I, which has been confirmed in Sweden and is spreading in Africa. The World Health Organization has declared it a global health emergency, with over 16,000 cases reported in Africa this year.

Vaccination Efforts and Treatment Challenges: Two vaccines have received emergency authorizations, with efforts to expand their use among at-risk populations. However, a study indicated that the antiviral drug tecovirimat did not reduce the duration of mpox lesions in affected individuals.